Eric Jhonsa
Technology Portfolio Manager at Dutch Asset
Astera Labs' valuation has gotten nuts given its medium- and long-term competitive and technology risks, especially next to NVIDIA and Broadcom. The aixPhotonics acquisition was smart, but even if those optical offerings ramp well, they are unlikely to offset the long-term cannibalization of retimers, AECs and similar products by NPO and CPO. x.comÂ
Astera Labs' competitive risks have been forgotten as markets focus on short- and medium-term growth and CXL hype, and an announcement or two could jog memories. Those risks include near- and co-packaged optics, NVLink and ESUN, Marvell and Broadcom encroaching further on its turf, and Amazon's in-house networking R&D. x.comÂ
Astera Labs looks relatively expensive because similarly fast-growing AI infrastructure names trade at much lower multiples. Broadcom and Nvidia are at 14x, Credo at 15x and Lumentum at 18x; comparable peers look 50-80% cheaper. Astera is a great company and not necessarily expensive in absolute terms. Its roughly 2x multiple over Credo may persist, but the setup looks harder; with no valuation support, it could fall 50% if weakness continues. x.com x.com x.com x.comÂ
Marvell risks paying a peak-scarcity price for Lumentum if optical supply catches up by 2028-30. The proposed ~$99B deal values Lumentum at roughly 20x guided annualized revenue and 58x estimated after-tax operating income, while Lumentum, Coherent and Chinese suppliers are adding laser capacity. The DSP-and-laser combination has strategic logic, but durable scarcity economics and Nvidia's response remain uncertain. x.comÂ
Astera Labs no longer looks expensive after falling 50% from its highs, trading below 35x NTM EBITDA with EBITDA expected to grow at a 60% CAGR for several years. Revenue is growing 105% YoY, with growth expected to accelerate for the next 2-3 quarters as margins expand. The stock is testing key support at its September 2025 highs, just above the 0.618 Fibonacci level and 200-day EMA. It is worth a look if the AI infrastructure buildout continues as planned. x.comÂ
Astera Labs is an amazing business, but its valuation is getting quite pricey. x.comÂ
Astera Labs carries a huge premium for flawless execution against a CXL market that is small near term. Switch-based CXL memory pooling capturing $15-16B in 2026-2028 is low probability: Marvell guides its XConn switch business to only about $100M by fiscal 2028, PCIe included. Pooling software likely stays immature into 2028, per a Samsung white paper, and Nvidia is contesting the warm KV-cache tier. Astera does CXL best, but SK hynix and Micron offer better risk-adjusted returns. x.com x.comÂ
Astera Labs is the next potential 10x long-term play for a young investor with high risk tolerance, as a leader in AI infrastructure connectivity whose semiconductor solutions power hyperscalers' rack-scale systems. x.comÂ
Astera Labs is a great company but definitely overvalued today. Per @StockSavvyShay, it carries a PEG ratio of about 3.6x, the highest among the semiconductor stocks compared and well inside the danger zone above 2x. x.comÂ
Interconnect, not compute, is now the binding constraint on AI clusters. Copper, pluggable optics and CPO will coexist for years, so the strongest names span both paths or own the tightest bottleneck. Top five: Credo, the fastest-growing full stack; Applied Optoelectronics, the 800G/1.6T ramp; Marvell, broadest but richly priced; Lumentum, the laser chokepoint; Tower, the foundry bet. Coherent, Amphenol, Fabrinet, GlobalFoundries, TSMC and Broadcom also gain. Astera Labs is pricier and narrower. … Show more
Astera Labs is an invisible hero of AI, as its retimers and fabric switches let thousands of GPUs operate as one massive supercomputer. Demand for its solutions has grown manyfold over the past year, driving explosive revenue growth, despite last year's fears that efficient models like DeepSeek would hurt AI infrastructure names. x.comÂ
Astera Labs is an incredible business, but its price leaves little margin of safety. Even an amazing decade, with revenue reaching $20B at 26% annual growth from about $1.9B, a 35% operating margin and a 30x multiple, makes it a roughly $158B company, about 3.6x from $44B, or around 13% a year before dilution. Slower revenue, lower margins, a lost customer, hyperscaler insourcing or tougher competition would erode that. Buying at half the price would make the risk/reward look amazing. x.com … Show more
